// App-Quantinova.ai

TCT-32 : First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients with de Novo Native Coronary Artery Lesions

Researchers

Presenter

  • Bernard Chevalier

Principal Investigators

  • N/A

Medical Centers

  • ICPS, Massy, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary artery lesions

  • Hypercholesterolemia, Familial, 1

  • Angina

  • Hypertension

  • Venous thrombosis

  • Coronary Artery Disease

  • Diabetes

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved